Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109648
Title:
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
Authors:
Gilleece, Maria H; Scarffe, J Howard; Ghosh, Anna K; Heyworth, Clare M; Bonnem, E; Testa, Nydia G; Stern, Peter L; Dexter, T Michael
Abstract:
Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.
Affiliation:
Cancer Research Campaign, Department of Experimental Haematology, Christie Hospital NHS Trust, Manchester, U.K.
Citation:
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial. 1992, 66 (1):204-10 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jul-1992
URI:
http://hdl.handle.net/10541/109648
PubMed ID:
1637669
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGilleece, Maria Hen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorHeyworth, Clare Men
dc.contributor.authorBonnem, Een
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorStern, Peter Len
dc.contributor.authorDexter, T Michaelen
dc.date.accessioned2010-08-16T14:27:48Z-
dc.date.available2010-08-16T14:27:48Z-
dc.date.issued1992-07-
dc.identifier.citationRecombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial. 1992, 66 (1):204-10 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid1637669-
dc.identifier.urihttp://hdl.handle.net/10541/109648-
dc.description.abstractRecombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshBone Marrow-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulin G-
dc.subject.meshInjections, Subcutaneous-
dc.subject.meshInterleukin-4-
dc.subject.meshLeukocyte Count-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshPlatelet Count-
dc.subject.meshReceptors, Interleukin-4-
dc.subject.meshReceptors, Mitogen-
dc.subject.meshRecombinant Proteins-
dc.titleRecombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Department of Experimental Haematology, Christie Hospital NHS Trust, Manchester, U.K.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.